Skip to main content
. Author manuscript; available in PMC: 2015 Jan 5.
Published in final edited form as: Transfusion. 2012 Feb 10;52(10):2209–2219. doi: 10.1111/j.1537-2995.2011.03550.x

Figure 1. CTLA4-Ig prevents humoral alloimmunization to LR-PLT.

Figure 1

(A) C57BL/6 recipients were administered a 500 µg dose of CTLA4-Ig i.p. two hours prior to each weekly transfusion of BALB/c LR-PLT concentrates. Sera was collected one week after each transfusion and tested for anti-donor antibodies using BALB/c splenocyte targets by indirect immunofluorescence staining. The middle panel shows individual animals whereas the right panel demonstrates combined data. (B) On day 0, C57BL/6 recipients were administered a single 500 µg dose of CTLA4-Ig i.p. two hours prior to a BALB/c LR-PLT transfusion. Recipients received four subsequent transfusions a week apart, on days 21, 28, 35, and 42. Sera was collected one week after each transfusion and tested for anti-BALB antibodies by indirect immunofluorescence staining using BALB/c splenocyte targets. Responders in (A) and (B) were defined as having an MFI two standard deviations above the mean MFI of the background sera from naïve C57BL/6 mice (dotted line). Error bars represent the mean ± SD. The combined data from three independent experiments are shown.